SPDR® S&P® Biotech ETF
Name
As of 03/26/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
Vitals
YTD Return
3.8%
1 yr return
23.7%
3 Yr Avg Return
-11.3%
5 Yr Avg Return
1.2%
Net Assets
$5.5 B
Holdings in Top 10
22.9%
52 WEEK LOW AND HIGH
Expenses
OPERATING FEES
Expense Ratio 0.35%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 74.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
N/A
IRA
N/A
Fund Classification
Fund Type
Exchange Traded Fund
Name
As of 03/26/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
XBI - Profile
Distributions
- YTD Total Return 3.8%
- 3 Yr Annualized Total Return -11.3%
- 5 Yr Annualized Total Return 1.2%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio 0.18%
- Dividend Yield 0.1%
- Dividend Distribution Frequency None
Fund Details
-
Legal NameSPDR® S&P® Biotech ETF
-
Fund Family NameState Street Global Advisors - advised funds
-
Inception DateFeb 06, 2006
-
Shares Outstanding83200000
-
Share ClassN/A
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerMichael Feehily
Fund Description
XBI - Performance
Return Ranking - Trailing
Period | XBI Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | 3.8% | -13.0% | 22.1% | 78.53% |
1 Yr | 23.7% | -19.6% | 37.7% | 12.27% |
3 Yr | -11.3%* | -30.2% | 13.9% | 92.95% |
5 Yr | 1.2%* | -2.8% | 14.5% | 92.65% |
10 Yr | 7.2%* | 0.3% | 14.3% | 74.77% |
* Annualized
Return Ranking - Calendar
Period | XBI Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | 7.6% | -12.6% | 19.0% | 16.56% |
2022 | -25.9% | -53.9% | 3.2% | 89.74% |
2021 | -20.5% | -39.6% | 24.2% | 86.54% |
2020 | 48.0% | -13.6% | 178.2% | 7.28% |
2019 | 32.6% | 3.8% | 63.8% | 9.63% |
Total Return Ranking - Trailing
Period | XBI Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | 3.8% | -13.0% | 22.1% | 78.53% |
1 Yr | 23.7% | -19.6% | 37.7% | 12.27% |
3 Yr | -11.3%* | -30.2% | 13.9% | 92.95% |
5 Yr | 1.2%* | -2.8% | 14.5% | 92.65% |
10 Yr | 7.2%* | 0.3% | 14.3% | 74.77% |
* Annualized
Total Return Ranking - Calendar
Period | XBI Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | 7.6% | -12.6% | 19.0% | 23.31% |
2022 | -25.9% | -53.9% | 3.7% | 91.67% |
2021 | -20.5% | -33.9% | 26.0% | 98.72% |
2020 | 48.3% | -0.7% | 180.6% | 7.28% |
2019 | 32.6% | 4.6% | 63.8% | 20.74% |
XBI - Holdings
Concentration Analysis
XBI | Category Low | Category High | XBI % Rank | |
---|---|---|---|---|
Net Assets | 5.5 B | 6.16 M | 45 B | 11.04% |
Number of Holdings | 126 | 23 | 413 | 11.04% |
Net Assets in Top 10 | 1.6 B | 2.07 M | 20.4 B | 20.25% |
Weighting of Top 10 | 22.88% | 18.1% | 77.0% | 94.48% |
Top 10 Holdings
- State Street Navigator Securities Lending Government Money Market Portfolio 7.98%
- Cytokinetics Inc 2.81%
- Karuna Therapeutics Inc 1.77%
- ACADIA Pharmaceuticals Inc 1.71%
- Biohaven Ltd 1.48%
- Amicus Therapeutics Inc 1.44%
- Blueprint Medicines Corp 1.43%
- Arrowhead Pharmaceuticals Inc 1.43%
- Bridgebio Pharma Inc 1.42%
- Moderna Inc 1.42%
Asset Allocation
Weighting | Return Low | Return High | XBI % Rank | |
---|---|---|---|---|
Stocks | 99.94% | 87.17% | 106.13% | 10.43% |
Cash | 8.90% | 0.00% | 32.99% | 12.27% |
Other | 0.00% | -22.99% | 17.73% | 31.90% |
Preferred Stocks | 0.00% | 0.00% | 7.86% | 81.60% |
Convertible Bonds | 0.00% | 0.00% | 0.37% | 72.78% |
Bonds | 0.00% | 0.00% | 12.39% | 75.46% |
Stock Sector Breakdown
Weighting | Return Low | Return High | XBI % Rank | |
---|---|---|---|---|
Healthcare | 100.00% | 59.26% | 100.00% | 34.81% |
Utilities | 0.00% | 0.00% | 0.00% | 71.52% |
Technology | 0.00% | 0.00% | 22.69% | 74.68% |
Real Estate | 0.00% | 0.00% | 5.89% | 74.05% |
Industrials | 0.00% | 0.00% | 7.02% | 74.68% |
Financial Services | 0.00% | 0.00% | 1.60% | 81.01% |
Energy | 0.00% | 0.00% | 0.00% | 71.52% |
Communication Services | 0.00% | 0.00% | 9.11% | 71.52% |
Consumer Defense | 0.00% | 0.00% | 25.73% | 74.68% |
Consumer Cyclical | 0.00% | 0.00% | 1.92% | 73.42% |
Basic Materials | 0.00% | 0.00% | 7.16% | 79.11% |
Stock Geographic Breakdown
Weighting | Return Low | Return High | XBI % Rank | |
---|---|---|---|---|
US | 99.94% | 66.21% | 104.41% | 6.75% |
Non US | 0.00% | 0.00% | 29.78% | 88.96% |
XBI - Expenses
Operational Fees
XBI Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Expense Ratio | 0.35% | 0.08% | 4.28% | 95.09% |
Management Fee | 0.35% | 0.03% | 1.25% | 7.36% |
12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
XBI Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Front Load | N/A | 3.50% | 5.75% | N/A |
Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
XBI Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
XBI Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Turnover | 74.00% | 0.00% | 238.00% | 88.41% |
XBI - Distributions
Dividend Yield Analysis
XBI | Category Low | Category High | XBI % Rank | |
---|---|---|---|---|
Dividend Yield | 0.06% | 0.00% | 6.97% | 36.20% |
Dividend Distribution Analysis
XBI | Category Low | Category High | Category Mod | |
---|---|---|---|---|
Dividend Distribution Frequency | None | Annually | Annual | Annual |
Net Income Ratio Analysis
XBI | Category Low | Category High | XBI % Rank | |
---|---|---|---|---|
Net Income Ratio | 0.18% | -2.54% | 1.85% | 27.56% |
Capital Gain Distribution Analysis
XBI | Category Low | Category High | Capital Mode | |
---|---|---|---|---|
Capital Gain Distribution Frequency | Annually | Annually | Annually | Annually |
Distributions History
Date | Amount | Type |
---|---|---|
Dec 21, 2023 | $0.014 | OrdinaryDividend |
Jun 23, 2023 | $0.003 | OrdinaryDividend |
Mar 25, 2021 | $0.040 | OrdinaryDividend |
Dec 24, 2020 | $0.176 | OrdinaryDividend |
Sep 24, 2020 | $0.089 | OrdinaryDividend |
Jun 25, 2020 | $0.017 | OrdinaryDividend |
Dec 26, 2019 | $0.001 | OrdinaryDividend |
Sep 25, 2019 | $0.003 | OrdinaryDividend |
Dec 27, 2018 | $0.012 | OrdinaryDividend |
Sep 26, 2018 | $0.073 | OrdinaryDividend |
Jun 20, 2018 | $0.059 | OrdinaryDividend |
Mar 21, 2018 | $0.059 | OrdinaryDividend |
Dec 26, 2017 | $0.035 | OrdinaryDividend |
Sep 25, 2017 | $0.037 | OrdinaryDividend |
Jun 26, 2017 | $0.110 | OrdinaryDividend |
Mar 27, 2017 | $0.020 | OrdinaryDividend |
Dec 27, 2016 | $0.018 | OrdinaryDividend |
Sep 26, 2016 | $0.031 | OrdinaryDividend |
Jun 27, 2016 | $0.046 | OrdinaryDividend |
Mar 29, 2016 | $0.058 | OrdinaryDividend |
Dec 29, 2015 | $0.149 | OrdinaryDividend |
Sep 28, 2015 | $0.050 | OrdinaryDividend |
Jun 29, 2015 | $0.146 | OrdinaryDividend |
Mar 30, 2015 | $0.082 | OrdinaryDividend |
Dec 30, 2014 | $0.164 | OrdinaryDividend |
Sep 29, 2014 | $0.188 | OrdinaryDividend |
Jun 30, 2014 | $0.205 | OrdinaryDividend |
Mar 31, 2014 | $0.111 | OrdinaryDividend |
Dec 31, 2013 | $0.013 | OrdinaryDividend |
Sep 30, 2013 | $0.029 | OrdinaryDividend |
Jul 01, 2013 | $0.017 | OrdinaryDividend |
Mar 25, 2013 | $0.015 | OrdinaryDividend |
Jan 04, 2013 | $0.066 | OrdinaryDividend |
Dec 31, 2009 | $0.001 | OrdinaryDividend |
Apr 01, 2009 | $0.050 | OrdinaryDividend |
Jan 02, 2009 | $0.002 | OrdinaryDividend |
Jul 02, 2008 | $0.224 | OrdinaryDividend |
Apr 02, 2008 | $0.009 | OrdinaryDividend |
Jan 04, 2008 | $0.007 | OrdinaryDividend |
XBI - Fund Manager Analysis
Managers
Michael Feehily
Start Date
Tenure
Tenure Rank
Oct 31, 2011
10.59
10.6%
Mr. Feehily, CFA, is a Managing Director of SSGA and the Adviser and Co-Head of Passive Equity Strategies in North America in the Global Equity Beta Solutions Group. In this capacity, Mr. Feehily has oversight of the North American Passive Equity teams in Boston and Montreal. In addition, Mr. Feehily is a member of the Senior Management Group. Mr. Feehily rejoined SSgA in 2010 after spending the previous four years at State Street Global Markets LLC where he helped to build the Exposure Solutions business.
Karl Schneider
Start Date
Tenure
Tenure Rank
Oct 31, 2014
7.59
7.6%
Karl Schneider, CAIA, is a Vice President of SSGA and SSGA FM, and Head of U.S. Equity Strategies for GEBS, where in addition to overseeing the management of the U.S. equity index strategies, he also serves as a portfolio manager for a number of the group's passive equity portfolios. Previously within GEBS, he served as a portfolio manager and product specialist for synthetic beta strategies, including commodities, buy/write, and hedge fund replication. Prior to joining GEBS, Mr. Schneider worked as a portfolio manager in SSGA's Currency Management Group, managing both active currency selection and traditional passive hedging overlay portfolios. He joined SSGA in 1996. Mr. Schneider holds a BS in finance and investments from Babson College and an MS in finance from Boston College. He has earned the Chartered Alternative Investment Analyst designation. Mr. Schneider is a member of the CAIA Association.
Raymond Donofrio
Start Date
Tenure
Tenure Rank
Jan 03, 2017
5.41
5.4%
Raymond Donofrio is a Vice President within SSGA and a Senior Portfolio Manager in the Global Equity Beta Solutions Group. Ray is currently responsible for managing various equity index funds, with both domestic and international strategies. Prior to his current role, Ray was an Analyst for SSGA's Strategy and Research group within the Global ETF Group. He began his career as an associate within the Investment Operations team at SSGA. He supported the Portfolio Managers of the Global Equity Beta Solutions team, mainly focusing on international strategies.
Tenure Analysis
Category Low | Category High | Category Average | Category Mode |
---|---|---|---|
0.02 | 24.72 | 7.84 | 0.25 |